logo
Antianxiety drugs in waterways are changing how salmon migrate

Antianxiety drugs in waterways are changing how salmon migrate

CNN16-04-2025

Summary
Antianxiety drug clobazam in waterways alters salmon migration behavior, causing fish to reach oceans sooner and navigate dams faster.
Researchers found benzodiazepine-exposed salmon showed reduced fear responses, swimming farther apart even when predators were near.
Swedish river studies tracked hundreds of young salmon implanted with time-release drug dispensers matching environmental pollution levels.
While more drug-exposed salmon reached the Baltic Sea, scientists warn these behavioral changes could harm long-term survival.
Griffith University researchers warn pharmaceutical pollution could reshape wildlife populations in unpredictable ways. Hatched in quiet streams and rivers, salmon undertake a perilous journey to reach the open ocean where they become mature adults. Over millions of years, generations of young salmon have migrated great distances, in some cases traveling hundreds of miles from freshwater systems to the sea. However, modern salmon face a hurdle that was unknown to their ancient ancestors: pharmaceutical pollution that changes their migration behavior.
Recently, researchers discovered that when a drug called clobazam accumulates in salmon's brains, migrating fish reach the ocean sooner and navigate dam obstacles faster. On the surface, this change might seem helpful to salmon. However, any deviation from normal animal behavior through human activity — particularly when psychoactive substances are involved — is a red flag, and the full extent of how drug pollution may alter salmon health, behavior and reproduction is still unknown, scientists reported April 10 in the journal Science.
Clobazam, which is commonly found in wastewater, belongs to a group of medicines called benzodiazepines, which depress the central nervous system. The drug is used to prevent epileptic seizures, for short-term treatment of anxiety and to treat anxiety-related sleep disorders. But because neural wiring in fish resembles that of mammals, fish are highly susceptible to the effects of drugs that tweak human neurochemistry, said Dr. Christopher C. Caudill, a professor in the department of fish and wildlife sciences at the University of Idaho.
'Humans share a large amount of biological architecture with fishes — our physiology and anatomy are remarkably similar. Thus, it is intuitive that psychoactive drugs alter the behavior of both fishes and humans,' Caudill, who was not involved in the research, told CNN in an email.
Prior research showed that benzodiazepines could alter behavior in Atlantic salmon (Salmo salar), but they did so under conditions unlike those experienced by wild salmon, said study coauthor Dr. Marcus Michelangeli, a lecturer in the School of Environment and Science at Griffith University in Queensland, Australia.
'Those studies were largely conducted in laboratory settings, only tracked movement over short distances — less than 100 metres (328 feet) — or used drug concentrations much higher than what salmon would typically encounter in the wild,' Michelangeli said via email.
'Our study took a different approach. We followed the entire river-to-sea migration of juvenile salmon in a natural river system, using drug concentrations that match what fish are actually exposed to in the environment.'
The field investigation's findings highlight the growing risks pharmaceutical pollutants pose to wildlife populations across the globe, according to Michelangeli.
For the new study, the scientists performed trials with more than 700 young salmon, or 'smolts,' in the laboratory and in the field. The research team used sound-transmitting tags to remotely track hundreds of smolts in 2020 and 2021 as the fish navigated the Dal River in central Sweden.
Migrating smolts swim downriver into a reservoir, hurtle over rapids and crest two dams before finally reaching the Baltic Sea. The journey takes 10 to 13 days.
Two major classes of pharmaceuticals — benzodiazepines and opioids — 'are commonly detected in rivers and streams worldwide, including in Sweden, where our study was conducted,' Michelangeli said.
Time-release implants in the smolts dispensed two drugs from these classes: clobazam and tramadol. Fish received clobazam, or tramadol, or both. A control group of smolts received implants with no drugs in them at all.
'These two drugs are known to interact chemically when taken together in humans, and they often co-occur in the environment,' Michelangeli said. 'This made them a good test case to explore how pharmaceutical mixtures might affect animal behaviour.'
Along with the field trials, the scientists ran a laboratory-based study on 256 smolts to confirm that the implants worked as intended and that the drugs were lingering in the fishes' bodily tissues and brains.
When the researchers tracked the migrating salmon with transmitters, they found that more clobazam-exposed salmon reached the Baltic than any of the other fish. Compared with the control group, more than twice as many salmon with clobazam implants made it to the sea.
Lab experiments showed that clobazam affected shoaling behavior, in which smolts stick close together to evade predators. Under the influence of clobazam, fish swam farther apart even when a predator was near, 'suggesting that the drug may reduce natural fear responses,' Michelangeli said.
Fish with clobazam implants were also faster at getting past two hydropower dams along their migration route — about two to eight times faster than fish in the other groups. These dams are notorious death zones, where churning turbines can swiftly reduce smolts to salmon tartare.
By diminishing fear in smolts, clobazam might briefly benefit the fish by boosting their migration success. But the drug could also increase their vulnerability to ocean predators, decreasing their chances of surviving long enough to return home to spawn, Caudill said.
'The transition from freshwater to saltwater is one of the most dangerous times in the life of a salmon because they experience many new predators in the ocean,' he said. Drug-exposed and risk-taking salmon may be more likely to reach the Baltic, but less likely to ever leave it alive.
Caudill's research investigates how environmental change affects fish ecology and evolution. In future work, he said, 'I do plan to consider the potential for behavioral effects from pharmaceutical pollution.'
Further study will clarify how behavioral changes from drug pollution affect long-term survival, reproduction and how populations change over time — in salmon and in other wildlife that are vulnerable to pharmaceutical contaminants.
'While more drug-exposed salmon may reach the sea, it doesn't mean they're healthy or that the population benefits in the long term,' Michelangeli said.
'The bottom line is we need to be cautious with this interpretation. Changing behaviour with pharmaceuticals — even unintentionally — could reshape whole populations in ways we don't yet understand.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

RFK Jr.: HHS Moves to Restore Public Trust in Vaccines
RFK Jr.: HHS Moves to Restore Public Trust in Vaccines

Wall Street Journal

time10 hours ago

  • Wall Street Journal

RFK Jr.: HHS Moves to Restore Public Trust in Vaccines

Vaccines have become a divisive issue in American politics, but there is one thing all parties can agree on: The U.S. faces a crisis of public trust. Whether toward health agencies, pharmaceutical companies or vaccines themselves, public confidence is waning. Some would try to explain this away by blaming misinformation or antiscience attitudes. To do so, however, ignores a history of conflicts of interest, persecution of dissidents, a lack of curiosity, and skewed science that has plagued the vaccine regulatory apparatus for decades.

‘We dissent': NIH scientists sign letter criticizing Trump's cuts in public health research
‘We dissent': NIH scientists sign letter criticizing Trump's cuts in public health research

Fast Company

time10 hours ago

  • Fast Company

‘We dissent': NIH scientists sign letter criticizing Trump's cuts in public health research

In his confirmation hearings to lead the National Institutes of Health, Jay Bhattacharya pledged his openness to views that might conflict with his own. 'Dissent,' he said, 'is the very essence of science.' That commitment is being put to the test. On Monday, scores of scientists at the agency sent their Trump-appointed leader a letter titled the Bethesda Declaration, challenging 'policies that undermine the NIH mission, waste public resources, and harm the health of Americans and people across the globe.' It says: 'We dissent.' In a capital where insiders often insist on anonymity to say such things publicly, 92 NIH researchers, program directors, branch chiefs and scientific review officers put their signatures on the letter — and their careers on the line. An additional 250 of their colleagues across the agency endorsed the declaration without using their names. The four-page letter, addressed to Bhattacharya, also was sent to Health Secretary Robert F. Kennedy Jr. and members of Congress who oversee the NIH. White House spokesman Kush Desai defended the administration's approach to federal research and said President Donald Trump is focused on restoring a 'Gold Standard' of science, not 'ideological activism.' Confronting a 'culture of fear' The signers went public in the face of a 'culture of fear and suppression' they say Trump's administration has spread through the federal civil service. 'We are compelled to speak up when our leadership prioritizes political momentum over human safety and faithful stewardship of public resources,' the declaration says. Bhattacharya responded to the declaration by saying it 'has some fundamental misconceptions about the policy directions the NIH has taken in recent months.' 'Nevertheless, respectful dissent in science is productive,' he said in a statement. 'We all want the NIH to succeed.' Named for the agency's headquarters location in Maryland, the Bethesda Declaration details upheaval in the world's premier public health research institution over the course of mere months. It addresses the termination of 2,100 research grants valued at more than $12 billion and some of the human costs that have resulted, such as cutting off medication regimens to participants in clinical trials or leaving them with unmonitored device implants. In one case, an NIH-supported study of multi-drug-resistant tuberculosis in Haiti had to be stopped, ceasing antibiotic treatment mid-course for patients. In a number of cases, trials that were mostly completed were rendered useless without the money to finish and analyze the work, the letter says. 'Ending a $5 million research study when it is 80% complete does not save $1 million,' it says, 'it wastes $4 million.' The mask comes off Jenna Norton, who oversees health disparity research at the agency's National Institute of Diabetes and Digestive and Kidney Diseases, recently appeared at a forum by Sen. Angela Alsobrooks, D-Md., to talk about what's happening at the NIH. At the event, she masked to conceal her identity. Now the mask is off. She was a lead organizer of the declaration. 'I want people to know how bad things are at NIH,' Norton told The Associated Press. The signers said they modeled their indictment after Bhattacharya's Great Barrington Declaration in 2020, when he was a professor at Stanford University Medical School. His declaration drew together likeminded infectious disease epidemiologists and public health scientists who dissented from what they saw as excessive COVID-19 lockdown policies and felt ostracized by the larger public health community that pushed those policies, including the NIH. 'He is proud of his statement, and we are proud of ours,' said Sarah Kobrin, a branch chief at the NIH's National Cancer Institute who signed the Bethesda Declaration. Cancer research is sidelined As chief of the Health Systems and Interventions Research Branch, Kobrin provides scientific oversight of researchers across the country who've been funded by the cancer institute or want to be. Cuts in personnel and money have shifted her work from improving cancer care research to what she sees as minimizing its destruction. 'So much of it is gone — my work,' she said. The 21-year NIH veteran said she signed because she didn't want to be 'a collaborator' in the political manipulation of biomedical science. Ian Morgan, a postdoctoral fellow with the National Institute of General Medical Sciences, also signed the declaration. 'We have a saying in basic science,' he said. 'You go and become a physician if you want to treat thousands of patients. You go and become a researcher if you want to save billions of patients. 'We are doing the research that is going to go and create the cures of the future,' he added. But that won't happen, he said, if Trump's Republican administration prevails with its searing grant cuts. The NIH employees interviewed by the AP emphasized they were speaking for themselves and not for their institutes nor the NIH. Dissenters range across the breadth of NIH Employees from all 27 NIH institutes and centers gave their support to the declaration. Most who signed are intimately involved with evaluating and overseeing extramural research grants. The letter asserts 'NIH trials are being halted without regard to participant safety' and the agency is shirking commitments to trial participants who 'braved personal risk to give the incredible gift of biological samples, understanding that their generosity would fuel scientific discovery and improve health.' The Trump administration has gone at public health research on several fronts, both directly, as part of its broad effort to root out diversity, equity and inclusion values throughout the bureaucracy, and as part of its drive to starve some universities of federal money. At the White House, Desai said Americans 'have lost confidence in our increasingly politicized healthcare and research apparatus that has been obsessed with DEI and COVID, which the majority of Americans moved on from years ago.' A blunt ax swings This has forced 'indiscriminate grant terminations, payment freezes for ongoing research, and blanket holds on awards regardless of the quality, progress, or impact of the science,' the declaration says. Some NIH employees have previously come forward in televised protests to air grievances, and many walked out of Bhattacharya's town hall with staff. The declaration is the first cohesive effort to register agency-wide dismay with the NIH's direction. The dissenters remind Bhattacharya in their letter of his oft-stated ethic that academic freedom must be a lynchpin in science. With that in place, he said in a statement in April, 'NIH scientists can be certain they are afforded the ability to engage in open, academic discourse as part of their official duties and in their personal capacities without risk of official interference, professional disadvantage or workplace retaliation.' Now it will be seen whether that's enough to protect those NIH employees challenging the Trump administration and him. 'There's a book I read to my kids, and it talks about how you can't be brave if you're not scared,' said Norton, who has three young children. 'I am so scared about doing this, but I am trying to be brave for my kids because it's only going to get harder to speak up.

US FDA approves Merck's RSV antibody for infants
US FDA approves Merck's RSV antibody for infants

Yahoo

time11 hours ago

  • Yahoo

US FDA approves Merck's RSV antibody for infants

(Reuters) -The U.S. Food and Drug Administration on Monday approved Merck's preventive antibody shot to protect infants up to one year of age from respiratory syncytial virus during their first RSV season, the company said. The United States has seen limited supply of Sanofi and AstraZeneca's antibody Beyfortus, the only preventive shot for RSV available in the country for infants and toddlers so far. Merck's therapy, called clesrovimab and branded as Enflonsia, is a monoclonal antibody that can be administered as a single dose regardless of birth weight in healthy pre-term, full-term and at-risk infants to protect them against mild, moderate and severe RSV. RSV is a common respiratory virus that causes seasonal infections such as the flu, but is a leading cause of pneumonia and death in infants and older adults. The approval was based on results from a late-stage trial in which Enflonsia had a comparable safety profile to Swedish Orphan Biovitrum's Synagis, a monthly injection. Merck said that Enflonsia is the first and only RSV preventive option administered to infants using the same dose regardless of weight, and it told Reuters the drug will be priced at $556 per dose. Jefferies analyst Akash Tewari said last year that this is beneficial since physicians have to forecast an infant's potential weight during RSV season with Beyfortus, which makes dose ordering and inventory more complex. In the U.S., an estimated 58,000–80,000 children younger than five years are hospitalized due to RSV each year, according to the U.S. Centers for Disease Control and Prevention. The CDC currently recommends two immunization options for babies to be protected from severe RSV — an RSV vaccine given to the mother during pregnancy or an RSV antibody given to the baby. Merck expects the drug's shipments to arrive in time for the 2025-2026 RSV season. The CDC's Advisory Committee on Immunization Practices is expected to meet later this month to discuss and make recommendations for the use of Enflonsia in infants.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store